| ■ 영문 제목 : Bronchodilators Market Size, Share & Trends Analysis Report By Disease (Asthma, COPD), By Route Of Administration (Inhalable, Oral), By Drug Class (Beta-Adrenergic, Anticholinergics), By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MA058
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 1월
■ 페이지수 : 130
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의약품
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)는 세계의 기관지 확장제 시장 규모가 2023년부터 2030년 사이에 연평균 3.29% 성장하여, 2030년에는 287.5억 달러에 이를 것으로 예측하고 있습니다. 본 조사 자료는 세계의 기관지 확장제 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 약물 등급별 (베타 아드레날린 작용성 기관지 확장제, 항콜린계 기관지 확장제, 크산틴 유도체) 분석, 투여 경로별 (경구, 흡입, 주사) 분석, 최종 용도별 (천식, COPD, 기타) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동/아프리카) 분석, 경쟁 현황 등의 내용을 게재하고 있습니다. 또한 본 자료는 Gsk Plc., Astrazeneca, Teva Pharmaceutical Industries Ltd., Cipla Inc., Mylan N.V., Merck & Co., Inc., Novartis Ag, Boehringer Ingelheim International Gmbh., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited 와 같은 기업 정보를 포함하고 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 기관지 확장제 시장 규모 : 약물 등급별
- 베타 아드레날린 작용성 기관지 확장제의 시장 규모
- 항콜린계 기관지 확장제의 시장 규모
- 크산틴 유도체의 시장 규모
・세계의 기관지 확장제 시장 규모 : 투여 경로별
- 경구 투여 기관지 확장제의 시장 규모
- 흡입 투여 기관지 확장제의 시장 규모
- 주사 투여 기관지 확장제의 시장 규모
・세계의 기관지 확장제 시장 규모 : 최종 용도별
- 천식에 사용되는 기관지 확장제의 시장 규모
- COPD에 사용되는 기관지 확장제의 시장 규모
- 기타 최종 용도에 사용되는 기관지 확장제의 시장 규모
・세계의 기관지확장제 시장 규모 : 지역별
- 북미의 기관지 확장제 시장 규모
- 유럽의 기관지 확장제 시장 규모
- 아시아 태평양의 기관지 확장제 시장 규모
- 중남미의 기관지확장제 시장 규모
- 중동/아프리카의 기관지 확장제 시장 규모
・경쟁 현황
・기업 정보 |
■ 보고서 개요Bronchodilators Market Growth & Trends
The global bronchodilators market is expected to reach USD 28.75 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 3.29% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the bronchodilators market is attributed to the increasing geriatric population and rising population with respiratory disorders. Moreover, respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma are more common among the elderly population.
The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders. The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD. For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC’s. This population has an accelerated rate of deterioration in lung function along with intensified mortality rate. As per American Lung Association, 17% of the population with asthma are smokers which is 13.7% in the non-asthmatic population. This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.
Moreover, there are increasing efforts from public and private organizations to increase awareness among the population. International organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are working with public health officials and healthcare professionals worldwide to increase awareness and improve the treatment and prevention of COPD around the world. Moreover, companies such as AstraZeneca, Cipla, Teva, and several others have been trying to spread awareness through social media platforms such as ‘Get Real’, #Laugh4Lungs’, ‘Inhalers are Right for Asthma’, ‘Inhaler is boon for Asthma’, and many more. These campaigns help raise awareness and encourage patients towards using more bronchodilators and enable them to secure their lives by taking preventive measures. Furthermore, the market is expected to grow due to regional market players ongoing R&D efforts to develop an effective treatment for patients with respiratory disorders.
Companies are collaborating to develop novel treatments to address unmet medical needs. This enables businesses to use their resources to help with product development and supply chain improvements. Moreover, a number of players are also focusing on product launches in order to expand their product portfolio. For instance, in September 2021, AstraZeneca started working on a combination formulation of inhaled corticosteroid (ICS) budesonide and beta2-agonist (SABA) albuterol for the treatment of patients with Asthma, which if approved is expected to be the first ICS/SABA combo rescue inhaler for asthma in the U.S.
Bronchodilators Market Report Highlights
• Beta adrenergic bronchodilators segment held a dominant share in the market in 2022, owing to the increasing number of generic approvals by the FDA to meet the rising demands
• Oral segment is projected to grow at the fastest rate over the forecast period attributable to it being the second most preferred mode of administration amongst clinicians and patients
• Asthma segment held a dominant share of the market in 2022 owing to the increasing prevalence of target diseases worldwide
• North America dominated the market in 2022, which is attributed to the presence of key market players in the region, highly developed healthcare infrastructure, better affordability
■ 보고서 목차Table of Contents
Chapter 1 Methodology And Scope
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.12 List Of Abbreviations
Chapter 2 Bronchodilators Market – Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Bronchodilators Market Variables, Trends & Scope
3.1 Bronchodilators Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.1.1 Global Asthma And Copd Market
3.1.2 Ancillary Market Outlook
3.1.2.1 Branded Generics Market
3.1.2.2 Hospital-Acquired Infection Therapeutics Market
3.2 Penetration And Growth Prospect Mapping
3.3 Market Driver Analysis
3.3.1 Growing Geriatric Population
3.3.2 Increasing Prevalence Of Lung Diseases
3.3.3 Rising Awareness About Treatment Of Lung Diseases
3.3.4. Increase In Number Of Smokers
3.3.5. Escalating R&D Efforts By Players
3.3.6. Heightened Pollution Levels Globally
3.4 Market Restraint Analysis
3.4.1 Long Approvals Times And Stringent Regulations
3.4.2 Adverse Effects Of Bronchodilators
3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
3.6 Porter’s Five Forces Analysis
3.7 Regulatory Framework
Chapter 4 Bronchodilators Market – Segment Analysis, By Drug Class, 2018 – 2030 (USD Million)
4.1 Definition And Scope
4.2 Bronchodilators Market: Drug Class Movement Analysis
4.2.1 Beta-Adrenergic Bronchodilators
4.2.1.1 Beta-Adrenergic Bronchodilators Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.2.2 Anticholinergic Bronchodilators
4.2.2.1 Anticholinergic Bronchodilators Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.2.3 Xanthine Derivatives
4.2.3.1 Xanthine Derivatives Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 5 Bronchodilators Market – Segment Analysis, By Route Of Administration, 2018 – 2030 (USD Million)
5.1 Bronchodilators Market: Route Of Administration Movement Analysis
5.1.1 Oral
5.1.1.1 Oral Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2 Nasal (Inhalable)
5.1.2.1 Nasal (Inhalable) Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3 Injectable
5.1.3.1 Injectable Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Bronchodilators Market – Segment Analysis, By End-Use, 2018 – 2030 (USD Million)
6.1 Definition And Scope
6.2 Bronchodilators Market: Disease Movement Analysis
6.2.1 Asthma
6.2.1.1 Asthma Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.2.2 Chronic Obstructive Pulmonary Disease (Copd)
6.2.2.1 Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.2.3 Others
6.2.3.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Bronchodilators Market – Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
7.7 North America
7.7.1 North America Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Bronchodilators Market, 2018 – 2030 (USD Million)
7.7.2.2 Key Country Dynamics
7.7.2.3 Regulatory Framework
7.7.2.4 Competitive Scenario
7.7.2.5 Recent Developments
7.7.2.6 Investments Scenario
7.7.3 Canada
7.7.3.1 Canada Bronchodilators Market, 2018 – 2030 (USD Million)
7.7.3.2 Key Country Dynamics
7.7.3.3 Regulatory Framework
7.7.3.4 Competitive Scenario
7.7.3.5 Recent Developments
7.7.3.6 Investments Scenario
7.8 Europe
7.8.1 Europe Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.2.2 Key Country Dynamics
7.8.2.3 Regulatory Framework
7.8.2.4 Competitive Scenario
7.8.2.5 Recent Developments
7.8.2.6 Investments Scenario
7.8.3 Germany
7.8.3.1 Germany Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.3.2 Key Country Dynamics
7.8.3.3 Regulatory Framework
7.8.3.4 Competitive Scenario
7.8.3.5 Recent Developments
7.8.3.6 Investments Scenario
7.8.4 Spain
7.8.4.1 Spain Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.4.2 Key Country Dynamics
7.8.4.3 Regulatory Framework
7.8.4.4 Competitive Scenario
7.8.4.5 Recent Developments
7.8.4.6 Investments Scenario
7.8.5 France
7.8.5.1 France Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.5.2 Key Country Dynamics
7.8.5.3 Regulatory Framework
7.8.5.4 Competitive Scenario
7.8.5.5 Recent Developments
7.8.5.6 Investments Scenario
7.8.6 Italy
7.8.6.1 Italy Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.6.2 Key Country Dynamics
7.8.6.3 Regulatory Framework
7.8.6.4 Competitive Scenario
7.8.6.5 Recent Developments
7.8.6.6 Investments Scenario
7.8.7 Denmark
7.8.7.1 Denmark Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.7.2 Key Country Dynamics
7.8.7.3 Regulatory Framework
7.8.7.4 Competitive Scenario
7.8.7.5 Recent Developments
7.8.7.6 Investments Scenario
7.8.8 Sweden
7.8.8.1 Sweden Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.8.2 Key Country Dynamics
7.8.8.3 Regulatory Framework
7.8.8.4 Competitive Scenario
7.8.8.5 Recent Developments
7.8.8.6 Investments Scenario
7.8.9 Norway
7.8.9.1 Norway Bronchodilators Market, 2018 – 2030 (USD Million)
7.8.9.2 Key Country Dynamics
7.8.9.3 Regulatory Framework
7.8.9.4 Competitive Scenario
7.8.9.5 Recent Developments
7.8.9.6 Investments Scenario
7.9 Asia Pacific
7.9.1 Asia-Pacific Bronchodilators Market, 2018 – 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Bronchodilators Market, 2018 – 2030 (USD Million)
7.9.2.2 Key Country Dynamics
7.9.2.3 Regulatory Framework
7.9.2.4 Competitive Scenario
7.9.2.5 Recent Developments
7.9.2.6 Investments Scenario
7.9.3 China
7.9.3.1 China Bronchodilators Market, 2018 – 2030 (USD Million)
7.9.3.2 Key Country Dynamics
7.9.3.3 Regulatory Framework
7.9.3.4 Competitive Scenario
7.9.3.5 Recent Developments
7.9.3.6 Investments Scenario
7.9.4 India
7.9.4.1 India Bronchodilators Market, 2018 – 2030 (USD Million)
7.9.4.2 Key Country Dynamics
7.9.4.3 Regulatory Framework
7.9.4.4 Competitive Scenario
7.9.4.5 Recent Developments
7.9.4.6 Investments Scenario
7.9.5 South Korea
7.9.5.1 South Korea Bronchodilators Market, 2018 – 2030 (USD Million)
7.9.5.2 Key Country Dynamics
7.9.5.3 Regulatory Framework
7.9.5.4 Competitive Scenario
7.9.5.5 Recent Developments
7.9.5.6 Investments Scenario
7.9.6 Thailand
7.9.6.1 Thailand Bronchodilators Market, 2018 – 2030 (USD Million)
7.9.6.2 Key Country Dynamics
7.9.6.3 Regulatory Framework
7.9.6.4 Competitive Scenario
7.9.6.5 Recent Developments
7.9.6.6 Investments Scenario
7.9.7 Australia
7.9.7.1 Australia Bronchodilators Market, 2018 – 2030 (USD Million)
7.9.7.2 Key Country Dynamics
7.9.7.3 Regulatory Framework
7.9.7.4 Competitive Scenario
7.9.7.5 Recent Developments
7.9.7.6 Investments Scenario
7.10 Latin America
7.10.1 Latin America Bronchodilators Market, 2018 – 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Bronchodilators Market, 2018 – 2030 (USD Million)
7.10.2.2 Key Country Dynamics
7.10.2.3 Regulatory Framework
7.10.2.4 Competitive Scenario
7.10.2.5 Recent Developments
7.10.2.6 Investments Scenario
7.10.3 Mexico
7.10.3.1 Mexico Bronchodilators Market, 2018 – 2030 (USD Million)
7.10.3.2 Key Country Dynamics
7.10.3.3 Regulatory Framework
7.10.3.4 Competitive Scenario
7.10.3.5 Recent Developments
7.10.3.6 Investments Scenario
7.10.4 Argentina
7.10.4.1 Argentina Bronchodilators Market, 2018 – 2030 (USD Million)
7.10.4.2 Key Country Dynamics
7.10.4.3 Regulatory Framework
7.10.4.4 Competitive Scenario
7.10.4.5 Recent Developments
7.10.4.6 Investments Scenario
7.11 MEA
7.11.1 MEA Bronchodilators Market, 2018 – 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Bronchodilators Market, 2018 – 2030 (USD Million)
7.11.2.2 Key Country Dynamics
7.11.2.3 Regulatory Framework
7.11.2.4 Competitive Scenario
7.11.2.5 Recent Developments
7.11.2.6 Investments Scenario
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia Bronchodilators Market, 2018 – 2030 (USD Million)
7.11.3.2 Key Country Dynamics
7.11.3.3 Regulatory Framework
7.11.3.4 Competitive Scenario
7.11.3.5 Recent Developments
7.11.3.6 Investments Scenario
7.11.4 UAE
7.11.4.1 UAE Bronchodilators Market, 2018 – 2030 (USD Million)
7.11.4.2 Key Country Dynamics
7.11.4.3 Regulatory Framework
7.11.4.4 Competitive Scenario
7.11.4.5 Recent Developments
7.11.4.6 Investments Scenario
7.11.5 Kuwait
7.11.5.1 Kuwait Bronchodilators Market, 2018 – 2030 (USD Million)
7.11.5.2 Key Country Dynamics
7.11.5.3 Regulatory Framework
7.11.5.4 Competitive Scenario
7.11.5.5 Recent Developments
7.11.5.6 Investments Scenario
Chapter 8 Bronchodilators Market – Competitive Analysis
8.1 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.2 Strategy Framework
8.3 Market Participation Categorization
8.4 Recent Developments & Impact Analysis, By Key Market Participants
8.5 Company Position Analysis
8.6 List Of Distributors
8.6.1 Key Customers
8.6.2 Public Companies
8.6.3 Private Companies
Chapter 9 Bronchodilators Market – Company Profiles
9.1 Company Profiles
9.1.1 Gsk Plc.
9.1.1.1 Company Overview
9.1.1.2 Financial Performance
9.1.1.3 Product Benchmarking
9.1.1.4 Strategic Initiatives
9.1.2 Astrazeneca
9.1.2.1 Company Overview
9.1.2.2 Financial Performance
9.1.2.3 Product Benchmarking
9.1.2.4 Strategic Initiatives
9.1.3 Teva Pharmaceutical Industries Ltd.
9.1.3.1 Company Overview
9.1.3.2 Financial Performance
9.1.3.3 Product Benchmarking
9.1.3.4 Strategic Initiatives
9.1.4 Cipla Inc.
9.1.4.1 Company Overview
9.1.4.2 Financial Performance
9.1.4.3 Product Benchmarking
9.1.4.4 Strategic Initiatives
9.1.5 Mylan N.V.
9.1.5.1 Company Overview
9.1.5.2 Financial Performance
9.1.5.3 Product Benchmarking
9.1.5.4 Strategic Initiatives
9.1.6 Merck & Co., Inc.
9.1.6.1 Company Overview
9.1.6.2 Financial Performance
9.1.6.3 Product Benchmarking
9.1.6.4 Strategic Initiatives
9.1.7 Novartis Ag
9.1.7.1 Company Overview
9.1.7.2 Financial Performance
9.1.7.3 Product Benchmarking
9.1.7.4 Strategic Initiatives
9.1.8 Boehringer Ingelheim International Gmbh.
9.1.8.1 Company Overview
9.1.8.2 Financial Performance
9.1.8.3 Product Benchmarking
9.1.8.4 Strategic Initiatives
9.1.9 Sun Pharmaceutical Industries Ltd.
9.1.9.1 Company Overview
9.1.9.2 Financial Performance
9.1.9.3 Product Benchmarking
9.1.9.4 Strategic Initiatives
9.1.10 Glenmark Pharmaceuticals Limited
9.1.10.1 Company Overview
9.1.10.2 Financial Performance
9.1.10.3 Product Benchmarking
9.1.10.4 Strategic Initiatives
|
| ※본 조사보고서 [세계의 기관지 확장제 시장 (2023~2030) : 천식, COPD] (코드 : GRV23MA058) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 기관지 확장제 시장 (2023~2030) : 천식, COPD] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
